We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find University Hospitals Doctors
Keming Gao, MD, PhD

Keming Gao, MD, PhD

  • Medical Director, Electroconvulsive Therapy, UH Cleveland Medical Center
  • Director, Mood Disorders Program, UH Cleveland Medical Center
  • Director, Ketamine Infusion for Depression Clinic, UH Cleveland Medical Center
  • Director, Repetitive Transcranial Magnetic Stimulation Clinic, UH Cleveland Medical Center
  • Professor, CWRU School of Medicine
  • Specialty: Psychiatry-Adult Psychiatry
  • Location:
    DO Walker Center
    10524 Euclid Ave
    Cleveland, OH 44106

Biography: Keming Gao, MD, PhD


  • Adult Psychiatry
  • Anxiety Disorders
  • Bipolar Disorders Research
  • Mood Disorders
  • Phenomenology and Psychopharmacotherapy

Certifications & Memberships

  • Psychiatry - American Board of Psychiatry and Neurology


Research Fellowship | Mood Disorders
Mood Disorders - University Hospitals Of Cleveland (2004 - 2006)

Residency | Psychiatry
Psychiatry - Metrohealth Medical Center (2000 - 2004)

Research Fellowship | Pharmacology
Pharmacology - Lsu Health Sciences Center-University Hospital (1994 - 1996)

Other Education
Shanghai Medical College Fudan University (1994)

Medical Education
Weifang Medical College (1985)


2006 Recipient of American Psychiatric Association Research Colloquium for Junior Investigators
2008 John C. and Sally S. Morley Family Foundation Award
2015 American Psychiatric Association Fellowship Award


Selected Publications

All Publications

  1. Gao K., Gajwani P., Elhaj O. and Calabrese JR. Typical and Atypical Antipsychotics in Bipolar Depression. J Clin Psychiatry 2005; 66: 1376-1385
  2. Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006; 67:1327-1340.
  3. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Calabrese JR. A Review of Sensitivity and Tolerability of Antipsychotics in Patients with Bipolar Disorder or Schizophrenia: Focus on Somnolence. J Clin Psychiatry 2008; 69:302-309.
  4. Gao K, Verduin ML, Kemp DE, Tolliver B, Ganocy SJ, Elhaj O, Brady K, Findling RL, Calabrese JR. Clinical Correlates of Patients With Rapid-Cycling Bipolar Disorder and a Recent History of Substance Use Disorder: A Subtype Comparison From Baseline Data of 2 Randomized, Placebo-Controlled Trials. J Clin Psychiatry 2008; 69(7):1057-63.
  5. Gao K, Kemp DE, Wang Z, Ganocy SJ, Conroy C, Serrano MB, Sajatovic M, Findling RL, Calabrese JR. Predictors of Non-Randomization during Open-Label Lithium and Divalproex Treatment in Rapid Cycling Bipolar Disorder: a Post-hoc Analysis of Two Studies. Psychopharmacology Bulletin, 2010, 43(1):23-38.
  6. Gao K, Wang Z, Chen J, Kemp DE, Chan PK, Conroy CM, Serrano MB, Ganocy SJ, Calabrese JR. Should an Assessment of Axis I Comorbidity be Included in the Initial Diagnostic Assessment of Mood Disorders? Role of QIDS-16-SR Total Score in Predicting Number of Axis I Comorbidity. Journal of Affective Disorders. 2013;148(2-3):256-64.
  7. Gao K, Wu R, Kemp DE, Chen J, Karberg E, Conroy C, Chan P, Ren M, Serrano MB, Ganocy SJ, Calabrese JR. Efficacy and Safety of Quetiapine-XR Monotherapy or Adjunctive Therapy to Mood Stabilizer in Acute Bipolar Depression with Generalized Anxiety Disorder and Other Comorbidities: A Randomized, Placebo-controlled Trial. Journal of Clinical Psychiatry, 2014 Oct;75(10):1062-8.
  8. Gao K, Wu R, Wang Z, Ren M, Kemp DE, Chan PK, Conroy CM, Mary Beth Serrano MB, Ganocy SJ, Calabrese JR. Disagreement between Self-Reported and Clinician-Ascertained Suicidal Ideation and Its Correlation with Depression and Anxiety Severity in Patients with Major Depressive Disorder or Bipolar Disorder. J Psychiatric Research, 2015; 60:117-124.
  9. Gao K, Fang F, Wang Z, Calabrese JR. Subjective Versus Objective Weight Gain During Acute Treatment With Second-Generation Antipsychotics in Schizophrenia and Bipolar Disorder. J Clin Psychopharmacol. 2016 Dec;36(6):637-642. Review.
  10. Gao K, Ganocy SJ, Conroy C, Brownrigg B, Serrano MB, Calabrese JR. A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use. Psychopharmacology (Berl). 2017 Aug;234(15):2233-2244. 
  11. Gao K, Su M, Sweet J, Calabrese JR. Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. J Affect Disord. 2019 Feb 1;244:9-15.

Research & Publications

Research Interests

Multi-Morbid Mood Disorders, Phenomenology and Treatment of Comorbid Anxiety Disorder in Mood Disorders

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Keming Gao did not disclose any Outside Relationships with Industry.